Nicox S.A.
ISIN: FR0013018124 | Ticker: COX | LEI: 969500EZGEO9W4JXR353
Country: France
Developing innovative ocular solutions
Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health.
We plan to keep the maximum of options open for the company by maintaining rights to our novel therapeutics for eye diseases in key territories, such as the U.S. and Europe, as we create value by advancing their development, maintaining the potential for direct marketing, licensing for certain territories and growth through strategic transactions.
We are focused on the discovery, development and commercialization of novel ophthalmic therapeutics for eye diseases.
1996
Served areaWorldwide
Headcount32
HeadquartersDrakkar 2 - Bâtiment D 2405 Route des Dolines, 6560 Valbonne – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Assets | N/A | 142,266,000.00 | 114,609,000.00 |
| Noncurrent Assets | N/A | 89,745,000.00 | 66,871,000.00 |
| Property Plant And Equipment | N/A | 1,166,000.00 | 1,023,000.00 |
| Goodwill | N/A | 23,663,000.00 | 25,637,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 64,848,000.00 | 39,974,000.00 |
| Other Noncurrent Financial Assets | N/A | 68,000.00 | 237,000.00 |
| Current Assets | N/A | 52,521,000.00 | 47,738,000.00 |
| Current Trade Receivables | N/A | 1,723,000.00 | 1,086,000.00 |
| Current Prepaid Expenses | N/A | 2,630,000.00 | 2,853,000.00 |
| Other Current Receivables | N/A | 736,000.00 | 1,452,000.00 |
| Cash and cash equivalents | 28,102,000.00 | 47,195,000.00 | 41,970,000.00 |
| Other Current Assets | N/A | 237,000.00 | 377,000.00 |
| Equity And Liabilities | N/A | 142,266,000.00 | 114,609,000.00 |
| Equity | 109,309,000.00 | 100,835,000.00 | 75,552,000.00 |
| Issued Capital | N/A | 37,030,000.00 | 43,138,000.00 |
| Retained Earnings | N/A | -467,144,000.00 | -508,892,000.00 |
| Share Premium | N/A | 528,595,000.00 | 536,200,000.00 |
| Treasury Shares | N/A | 605,000.00 | 847,000.00 |
| Noncurrent Liabilities | N/A | 26,027,000.00 | 31,057,000.00 |
| Noncurrent Provisions | N/A | 730,000.00 | 661,000.00 |
| Deferred Tax Liabilities | N/A | 11,868,000.00 | 9,236,000.00 |
| Current Liabilities | N/A | 15,404,000.00 | 8,000,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 2,421,000.00 | 3,649,000.00 |
| Other Current Liabilities | N/A | 2,163,000.00 | 2,035,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
|---|---|---|
| Revenue | 12,907,000.00 | 7,233,000.00 |
| Revenue From Contracts With Customers | 14,423,000.00 | 8,583,000.00 |
| Other Income | 1,083,000.00 | 843,000.00 |
| Amortisation Expense | 1,252,000.00 | 1,205,000.00 |
| Profit Loss From Operating Activities | -6,760,000.00 | -46,010,000.00 |
| Finance Income | 1,168,000.00 | 3,456,000.00 |
| Finance Costs | 12,478,000.00 | 4,851,000.00 |
| Profit Loss Before Tax | -18,070,000.00 | -47,405,000.00 |
| Income Tax Expense Continuing Operations | 28,000.00 | -3,644,000.00 |
| Profit (loss) | -18,098,000.00 | -43,761,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Profit (loss) | N/A | -18,098,000.00 | -43,761,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | 128,000.00 | -716,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 1,743,000.00 | 29,421,000.00 |
| Adjustments For Provisions | N/A | 6,000.00 | -67,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 2,290,000.00 | -2,276,000.00 |
| Adjustments For Sharebased Payments | N/A | 1,314,000.00 | 1,463,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | 0.00 | -8,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -5,392,000.00 | -18,481,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 20,000.00 | 8,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 0.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | 4,949,000.00 | -175,000.00 |
| Proceeds From Issuing Shares | N/A | 13,954,000.00 | 13,713,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 633,000.00 | -91,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 380,000.00 | 395,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 19,584,000.00 | 13,409,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 19,141,000.00 | -5,246,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -48,000.00 | 21,000.00 |
| Cash and cash equivalents | 28,102,000.00 | 47,195,000.00 | 41,970,000.00 |
Please note that some sums might not add up.
FR0013018124
LEI969500EZGEO9W4JXR353
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.